Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Glioma × apatinib × Clear all

Status

Sponsor Class

Study Type

Interventional 3 Observational 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 1 Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety 1 Lung Neoplasms 1 Liver Neoplasms 1 Glioma 1 Glioblastoma 1 Carcinoma, Hepatocellular 1 Breast Cancer Organoids 1 Advanced Gastric Cancer 1

Interventions

Blood Specimen Collection 8 Surveys and Questionnaires 6 Radiotherapy 6 Magnetic Resonance Spectroscopy 6 Surgical Procedures, Operative 4 Temozolomide 3 Aminolevulinic Acid 3 vorasidenib 2 X-Rays 2 Polymerase Chain Reaction 2 Neuropsychological Tests 2 Magnetic Resonance Imaging 2 Diagnostic Imaging 2 Cancer Vaccines 2 Amplified Fragment Length Polymorphism Analysis 2 vinyltriethoxysilane 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 gadoterate meglumine 1 gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate 1 fluorodopa F 18 1 fluarix 1 apatinib 1 Ultrasonography 1 Transurethral Resection of Bladder 1 Trail Making Test 1 Tetanus Toxoid 1 Radiation 1 Proton Therapy 1 Positron Emission Tomography Computed Tomography 1 Pharmacogenomic Testing 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04216550 2021-02-08

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

The First Affiliated Hospital of Zhengzhou University

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡